Dendritic cells and lymphotropic viruses: Who is fooling whom?
Throughout our early ancestors, our immune system has evolved into a very sophisticated system to combat invading pathogens. In turn, pathogenic viruses have evolved and are continuously evolving new mechanisms to escape the immune system, increasing their survival in the host and their spread throughout the population 1, 9, 19, 57 .
This thesis describes the interaction of viruses with a specific type of immune cells: the dendritic cells (DCs). DCs are essential for the induction of an antiviral immune response 6 . However, viruses, especially lymphotropic viruses, are thought to subvert DC function for transport from the site of entry into the lymphoid tissues 57 . Furthermore, viruses may target DC function to modulate the immune system during established infection, thereby increasing their survival and dissemination to subsequent hosts 1 . We have focussed on the first interaction between viruses and DCs at the site of infection. We have studied two lymphotropic viruses: human immunodeficiency virus (HIV-1) and measles virus (MV). We investigated their interaction with different DC subtypes, including DC-SIGN + DCs and Langerhans cells. While employing virological and immunological assays, we kept asking ourselves: "Are our observations beneficial to the host or to the virus?" In this general introduction I will briefly introduce the key players, basic concepts, and main questions of this thesis.
Dendritic cells have a unique position in the immune system
The immune system can be divided into the innate and adaptive immune system. Innate mechanisms respond fast and provide a first-line of defence against various invading micro-organisms. In contrast, adaptive immune responses are relatively slow in onset, pathogen-specific and enable memory to prevent illness by a second attack with the same pathogen. The cell type that bridges the innate and adaptive immune system is the DC. DCs are present at strategic sites to sense invading pathogens, such as the peripheral tissues that line the external environment, including the skin and mucosa ( Figure  1 .1). At the site of infection, cells of the innate immune system as well as DCs are activated. The innate immune cells perform their immunological function at the site of infection, whereas DCs capture pathogens and migrate towards the lymphoid tissues, to induce an adaptive immune response ( Figure  1 .1). Thus, DCs operate at the interface of both the innate and adaptive immune system 6, 28, 29, 58 .
Dendritic cells are professional antigen presenting cells.
Antigen presenting cells (APCs) internalize antigens for degradation into peptides, which are displayed on MHC class molecules to prime naïve T cells. APCs comprise of B cells, macrophages and DCs. DCs are the most efficient APCs at activating naïve T cells and are therefore called "the professional APCs" 6, 60 .
DCs were named after their unique cytoplasmic extensions, referred to as dendrites 56 . DCs are derived from haematopoietic precursor cells 54 and migrate from the bone marrow via the blood to seed in different sites of the body, where the cells they have an immature state. Immature DCs are characterized by a high endocytic capacity, which enables them to sample the surrounding environment for invading pathogens or environmental triggers. Upon antigen encounter, DCs acquire a mature phenotype: their dendritic processes are prolonged; they up-regulate cell-surface receptors that act as co-stimulatory molecules in T cell activation such as CD80, CD83 and CD86, and the increase CCR7 expression, a chemotactic receptor that mediates DC migration into the lymphoid tissues 37, 55, 59 . In the meantime, DCs process the internalized antigen into peptides, which are presented in the context of major histocompatibility complex (MHC) class molecules 43, 61 . To prime antigen specific CD4 + T cells two signals are required: the specific interaction of the MCH class-II:peptide complex with the T cell receptor and a co-stimulatory signal provided by the maturation markers on DCs 50 . In addition to MHC class-II presentation, it is now evident that DCs present peptides derived from internalized antigen in the context of MHC class-I, a process referred to as cross-presentation 4, 25, 61 . 
Pattern-recognition receptors on dendritic cells
DCs express different classes of pathogen receptors, including pattern recognition receptors (PRRs) 22, 24, 29 . PRRs recognize small molecular motifs that can be found on pathogens. Two main families of PRRs are the Toll-like receptors (TLRs) and the C-type lectins 10, 23, 42 . TLRs recognize a variety of pathogenic structures, including viral RNAs. TLR signaling results in DC maturation as well as cytokine production 27, 33, 36 . C-type lectins recognize carbohydrate structures on pathogens 16 , facilitating pathogen capture and internalization 22, 23 . This receptor family is not only important in antigen presentation, but might adjust the immune response by cross-talk with TLRs 20,62 .
Viruses
Although very small, and often comprised of only a few different proteins, viruses are masters of manipulating their host for replication, survival and spread 17 . A virus is unable to grow or replicate autonomously, and therefore uses the machinery and metabolism of a host cell to replicate. Viruses use specific receptors to mediate attachment and fusion of the viral-and cell membrane. This specificity largely determines the viral host range (e.g. human, bird) and within the host, viral tropism (host cell of the virus e.g. T cell, epithelial cell). Here we have focussed on lymphotropic viruses that have a specific tropism for lymphocytes, but might also infect macrophages, dendritic cells and other leukocytes 17 .
Viral transmission
To initiate infection, a virus needs to approach and attach to the body surfaces of a novel host. Subsequently, the virus must reach its target organs, infect its host cells and start the replication cycle. All of these processes have to occur, while encountering the host defense mechanisms, such as the surface barriers, the innate immune system and the starting adaptive immune response. Transmission of viruses from an infected host to a susceptible individual occurs in different ways, such as via aerosols, by sexual contact, faecal-oral contamination, and direct inoculation via infected needles or an insect bite. The tropism and transmission route of a virus dictates the mechanisms a virus employs to colonize the host 17 . For example, a rhinovirus, the causative agent of the common cold enters the body via the upper respiratory tract. Here, the surface barriers destroy a part of the virus. However a small population of the virus survives and reaches the surface of the epithelial cells. The virus binds to its entry receptor, enters the cell and replication is started 7 . For this virus, the processes of entry, primary replication, and tissue tropism all occur at the same anatomic localization (Figure 1.2) 7,17 .
Other viruses, however, enter the body at one site and, in order to produce disease, spread to a distant area. For these viruses, classical textbooks 3,17 distinguish between primary viral replication near the entry site of infection and secondary replication at the target organ for infection. However, viruses that are unable to infect cells at the site of entry (e.g. HIV-1) are thought to use other mechanisms to reach their target cells.
In vitro and ex vivo studies have suggested a prominent role for DCs in the transmission of lymphotropic viruses 48, 57, 65 . To elicit their function in the immune system, DCs mediate transport of antigens from the periphery towards the lymphoid tissue, thereby bridging the site of entry of the lymphotropic virus with their site of replication. Viruses are therefore thought to hijack DC function to gain access into regions rich of viral host cells. This mechanism allows these viruses to bypass the normally impermeable mucosal barrier where their target cells are scarce and the innate immune response might destroy them (Figure 1.2) . 
Anti-viral immune response in acute infections
Human body surfaces are equipped with mechanical and chemical barriers to stop invading pathogens. These mechanical barriers include impermeable tight junctions between the epithelial/epidermal cells, the thick and dry keratin layer of the skin, the mucus which traps viruses, and actions, such as sneezing and flushing to abandon approaching viruses. Chemical barriers consist of the low pH of the body fluids and antimicrobial products (defensins, lysozyme, pepsin) that are secreted at the body surfaces 8, 29, 34, 44 . After viral entry into the host, the innate immune system is activated by the interaction of viruses with different PRRs 31, 32, 47 After a couple of days, the adaptive immune system is primed by APCs. A cellular response is induced, including the activation of cytotoxic T-lymphocytes (CTLs), that specifically kill viral-infected cells and which are essential for clearing a primary viral infection 17 . Moreover, memory B and T lymphocytes are induced to prevent re-infection 29 .
Subsets of dendritic cells and their role during viral infections
DCs are a heterogeneous population of cells, which consist of different subsets, based on the expression of markers and functional capacities 63 . Roughly, DCs can be divided into myeloid DCs and plasmacytoid DCs (pDCs) 12, 13, 49 . PDCs are primarily located in blood and lymphoid organs, but they are also found at sites of inflammation . Thus, viruses continuously evolve strategies to subvert DC function; however, most of the underlying mechanisms still remain to be elucidated. A better understanding will lead to more insight into our immune system and viral pathology.
Studying viral transmission to stop viral epidemics
To slow down or cure a viral epidemic, infections need to be cleared or prevented. Since viruses are small, use the host cell machinery to replicate, and rapidly mutate, targets for antiviral drugs are scarce and are quickly evaded by the virus. The last decades several effective antiviral drugs have been developed. Nevertheless most viral infections still lack a curative treatment. The best way to restrict an epidemic is to prevent new infections. Moreover, prevention is the only method to impede viral epidemics without a curative treatment. Vaccination has been the most successful viral prevention method, resulting in the eradication of smallpox, and a strong reduction of the incidence of polio, measles and rubella 3 . However, vaccines are not available for every virus, especially not for viruses that are rapidly mutating, such as HIV-1 39, 41, 46 . Therefore genital creams or gels containing antiviral compounds ('microbicides') are being developed, aiming to prevent HIV-1 transmission 5, 38, 45 .
The first results have indicated that different viruses use similar molecular mechanisms to infect a host. Hypothetically, interference with these mechanisms might provide a solution to stop a pandemic caused by an unknown virus. Moreover, unravelling these mechanisms will provide insights in how our immune system interacts with viruses, which could result in better vaccination strategies 38 .
Thesis outline
In this thesis I will describe our investigations on viral transmission with a focus on two lymphotropic viruses: HIV-1 and MV. HIV-1 and MV are very different in some aspects, but also share similarities (Table 1) . . A large number of studies have further investigated the interaction between HIV-1 and DCs. However, the receptors involved in this process have been strongly debated. In Section 2 we will discuss the current knowledge on the interaction between HIV-1 and an important DC subset, the DC-SIGN + DCs. We will show new data on the internalisation of HIV-1 in DC-SIGN + DCs, visualized using electron-microscopy and demonstrate that DCs also express another novel HIV-1 attachment receptor on DCs, which is called syndecan-3. In Section 4, we have addressed the specificity of DC-SIGN for viral ligands. The interaction of DC-SIGN with herpes simplex virus and human papilloma virus like particles was examined. The role of DC-SIGN in our immune system will be further discussed. In Section 5, we have investigated the role of different DC subsets at the site of viral entry. We have observed that LCs are not efficiently infected with HIV-1 compared to DC-SIGN + DCs. The C-type lectin Langerin efficiently captures virus for degradation, leading to protection of LCs and other target cells against HIV-1 infection. These results suggested that LCs fulfil an innate antiviral barrier function, protecting the host against invading viruses. We have therefore determined whether this protective function is specific for HIV-1 or whether it applies to more viruses, such as MV. Furthermore, we have investigated whether capture of viruses by Langerin results in antigen presentation in the context of MHC-class-II and cross-presentation in the context of MHC-class-I.
In Section 6, we will describe how risk factors contribute to HIV-1 transmission. The presence, density and phenotype of LCs have been characterized in different genital tissues. Furthermore, we have investigated how LCs respond to co-infection with either herpes simplex virus, bacterial or fungal pathogens, and how this altered LC phenotype affects the susceptibility to HIV-1 transmission. In Section 7 we will elaborate on the implications of the previous sections for the prevention of HIV-1 transmission. We have investigated the impact of candidate antiviral compound C5A on viral transmission. In the final Section 8, we will answer the question "Dendritic cells and lymphotropic viruses: Who is fooling whom?" We will discuss our data on a molecular, viral, cellular, host and global level. Data in this thesis and experimental/epidemiological data of others indicate that HIV-1 transmission should not be considered as a static but a fluid process, depending on the exposed tissue, viral loads of the infected partner, environmental and host factors. We will propose a ´multi-layered´ model to describe HIV-1 transmission, to discuss what research is needed to understand viral transmission and to ultimately stop transmission of severe viral pandemics.
